Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin versus medroxyprogesterone acetate for symptomatic uterine fibroids
IRCT20260417069087N1Phase 3Completed
- Sponsor
- Jahrom University of Medical Sciences
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Fibromyoma (LM) comparing Triptorelin with Medroxyprogesterone acetate (2 arms). Primary endpoint: Need for myomectomy surgery. Started May 2026; status: completed.
02
Drugs
triptorelinmedroxyprogesterone acetate
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20260417069087N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260417069087N1.